Loading…
← CockpitCompetitor Analysis › 2256.HK Abbisko Cayman LimitedOpen in the cockpit ↗

Abbisko Cayman Limited2256.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Momentum laggard 16
Mkt cap
$578M
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$1.88M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.8%
Hurdle
n/a
no reverse DCF
Next earnings
120 days
18 Mar 2027
Close · HKDHK$6.30
1D0.0%
1W-5.3%
1M-16.9%
3M-38.2%
6M-38.7%
YTD-51.6%
1Y-55.9%
ATR %8.0%
52w lowhigh58.0% off high

What Abbisko Cayman does

Employees: 276

Abbisko Cayman at a glance

Size Abbisko Cayman (2256.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $578M, the 713th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$6.30 on 18 Nov 2026.

Performance Over six months the shares fell 38.7%, against -23.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue fell 83.3% over the last twelve months (peer median +2.2%); the operating margin is -519.6% (peer median 5.6%).

Valuation It trades at 20.1× enterprise value to sales against a peer median of 3.1× (4th most expensive of 17).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 762256.HK 63
Six months, rebased to 100: Abbisko Cayman against the median of its 20 peers (local-currency closes).

Abbisko Cayman financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$111MHK$664MHK$546MHK$21.1MHK$0
Revenue growth—+21%+2,495%——
Gross profitHK$84.8MHK$640MHK$521MHK$704,989-HK$18.4M
EBITDA-HK$552MHK$54.5MHK$2.14M-HK$544M-HK$560M
Net income-HK$520MHK$59.9MHK$30.7M-HK$477M-HK$576M
Free cash flow-HK$390MHK$142MHK$40.4M-HK$443M-HK$399M
Capital expenditureHK$4.70MHK$6.00MHK$8.02MHK$13.5MHK$26.5M
Total debtn/aHK$338MHK$25.8MHK$39.3MHK$51.2M

Quarterly statements and history in the cockpit →

Abbisko Cayman competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-30%-20%-10%-20%0%361347432157603439CGEMALMSENTX300147688356600568IMMX600976002393301096003850300233DBVZVRA45592256.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Abbisko Cayman is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×361347432157603439ALMS300147688356ACRS301096ZVRA45592256.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Abbisko Cayman is the large dot.

Abbisko Cayman competitors and peer comparison

How Abbisko Cayman compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Abbisko Cayman against its 20 peers (data as of 18 Nov 2026)
Measure2256.HKPeer medianRank in peer set
1-month return-16.9%-11.1%6th lowest of 21
6-month return-38.7%-23.4%5th lowest of 21
Distance from 52-week high-58.0%-43.4%5th lowest of 21
Revenue growth (TTM)-83.3%+2.2%2nd lowest of 18
Operating margin-519.6%5.6%4th lowest of 17
EV / Sales20.1×3.1×4th most expensive of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%20.1×n/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%1.9×-15.4%+2.8%
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%23.9×n/an/a
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Jenkem Technology 688356.SSChina$563M-30%+52%11%8.7×36.4%+11.2%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%6.2×n/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%1.2×-5.8%+4.1%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%69.1×n/an/a
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Boryung 003850.KSSouth Korea$554M-13%+6%6%0.9×-3.1%+12.6%
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%2.4×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%1.0×-12.3%+11.1%

Questions

Which companies are Abbisko Cayman's closest peers?
The cockpit's peer set: Beijing Tong Ren Tang Chinese Medicine (3613.HK), Oneness Biotech (4743.TWO), Lepu Biopharma (2157.HK), GuiZhou SanLi Pharmaceutical (603439.SS), Cullinan Therapeutics (CGEM), Alumis (ALMS), Entera Bio (ENTX), Xiangxue Pharmaceutical (300147.SZ).
Is Abbisko Cayman expensive compared with its peers?
On ev / sales it trades at 20.1× against a peer median of 3.1×, 4th most expensive of 17 in its peer set.
How has Abbisko Cayman stock performed?
Over six months to 18 Nov 2026 the shares returned -38.7% against -23.4% for the median peer; over one year -55.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.